Open AccessImpact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)
Author(s) -
J.B. Auliac,
Florian Guisier,
A. Bizieux,
P. Assouline,
Marie Bernardini,
R. Lamy,
G. Justeau,
G François,
Diane Damotte,
C. Chouaïd
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s288825
Subject(s) - medicine , lung cancer , chemotherapy , oncology , immunotherapy , cancer , gastroenterology
Few data have been published on the clinical and histopathological characteristics of advanced non-small-cell lung cancer (NSCLC) patients with high PD-L1 expression versus intermediate or none and the prognostic value of PD-L1 expression for patients treated with chemotherapy is unknown. This study was undertaken to prospectively assess the prognostic value of tumor-cell (TC) and immune-cell (IC) PD-L1 expressions for advanced NSCLC patients.